Europe Drug Discovery Platforms Market Size, Share & Industry Analysis Report By Drug Type (Small Molecule, and Large Molecule), By End Use (Biopharmaceutical Companies, Academic and Research Institutes and CROs/CDMO), By Application (Lead Discovery, and Lead Optimization), By Therapeutic, By Country Outlook and Forecast, 2026 - 2033

The Europe Drug Discovery Platforms Market is expected to reach USD 1,983.28 Million by 2031, growing at a CAGR of 14.4% during 2026 - 2033.

The Europe Drug Discovery Platforms Market has evolved from conventional biochemical assays and laboratory-based screening techniques toward highly integrated, AI-enabled discovery ecosystems. Historically, pharmaceutical research across Europe relied heavily on manual target identification, high-throughput screening, and combinatorial chemistry to identify promising therapeutic candidates. Over the years, advances in computational biology, molecular modeling, automation, bioinformatics, and multi-omics technologies have transformed the regional drug discovery landscape.

The emergence of artificial intelligence (AI), machine learning (ML), cloud computing, translational science, organ-on-chip technologies, and systems biology has significantly improved target identification, lead optimization, predictive toxicology, and preclinical research. Today, Europe represents one of the world's most advanced drug discovery ecosystems, supported by strong pharmaceutical innovation, extensive academic research networks, biotechnology clusters, and a highly regulated environment that encourages high-quality, data-driven pharmaceutical development.

Drug Type Outlook

Based on Drug Type, the Europe market is segmented into Small Molecule and Large Molecule. The Small Molecule market dominated the Europe Drug Discovery Platforms Market by Drug Type in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1,442.69 Million by 2031, growing at a CAGR of 14.1 % during the forecast period. The Large Molecule market is expected to witness a CAGR of 15.2% during (2026 - 2033).

Small Molecule platforms account for the largest share owing to their extensive use in medicinal chemistry, high-throughput screening, computational chemistry, and structure-based drug design across pharmaceutical research. Large Molecule platforms continue to witness strong growth driven by increasing investments in biologics, monoclonal antibodies, recombinant proteins, peptides, gene therapies, and cell therapies. Advances in protein engineering, AI-assisted biologics discovery, CRISPR technologies, and next-generation sequencing continue to strengthen adoption across Europe.

Application Outlook

Based on Application, the market is segmented into Lead Discovery, Lead Optimization, Target Identification, Preclinical Testing, Target Validation, and Other Applications. Lead Discovery dominates the market owing to increasing adoption of virtual screening, AI-powered compound identification, and high-throughput screening technologies. Lead Optimization benefits from predictive chemistry, ADMET modeling, medicinal chemistry, and computational simulations. Target Identification and Target Validation continue to expand through genomics, proteomics, CRISPR screening, and systems biology applications. Preclinical Testing is witnessing increasing adoption of organ-on-chip technologies, advanced 3D cell culture models, predictive toxicology platforms, and AI-enabled safety assessment systems.

End User Outlook

Based on End Use, the market is segmented into Biopharmaceutical Companies, CROs/CDMOs, and Academic & Research Institutes. The Biopharmaceutical Companies market dominated the Europe Drug Discovery Platforms Market by End Use in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1,037.18 Million by 2031, growing at a CAGR of 13.9 % during the forecast period. The CROs/CDMO market is expected to witness a CAGR of 14.9% during (2026 - 2033). The Academic and Research Institutes market is expected to witness a CAGR of 15.1% during (2026 - 2033).

Biopharmaceutical Companies account for the largest market share owing to significant investments in drug development, expanding therapeutic pipelines, and rapid adoption of AI-enabled drug discovery technologies. CROs and CDMOs continue to experience strong growth as pharmaceutical companies increasingly outsource discovery and preclinical research activities to improve operational efficiency and reduce development costs. Academic and Research Institutes remain important contributors through translational research, biomarker discovery, target identification, and collaborative innovation programs supporting next-generation therapeutics.

Therapeutic Area Outlook

Based on Therapeutic Area, the market is segmented into Oncology, Infectious & Immune System Diseases, Neurology, Cardiovascular Diseases, Digestive System Diseases, and Other Therapeutic Areas. Oncology represents the largest therapeutic segment owing to increasing investments in precision oncology, biomarker discovery, immunotherapies, and targeted drug development. Infectious & Immune System Diseases continue to benefit from growing research into vaccines, antimicrobial resistance, and immunomodulatory therapies. Neurology is witnessing increasing adoption of advanced discovery platforms for neurodegenerative disorders, while cardiovascular and digestive disease research continue to generate consistent demand for AI-enabled drug discovery technologies throughout Europe.

Free Valuable Insights: The Worldwide Drug Discovery Platforms Market is projected to reach USD 9,879.2 Million billion by 2033, at a CAGR of 14.8%

Country Outlook

The Europe Drug Discovery Platforms Market is analyzed across Germany, the United Kingdom, France, Russia, Spain, Italy, and Rest of Europe. The Germany and UK led the Europe Drug Discovery Platforms Market by Country with a market share of 20.1% and 18% in 2025.The Spain market is expected to witness a CAGR of 16.2% during throughout the forecast period.

Germany leads the regional market owing to its strong pharmaceutical manufacturing base, advanced biotechnology ecosystem, and substantial R&D investments. The United Kingdom remains a major innovation hub driven by AI-enabled drug discovery, academic excellence, and biotechnology startups. France continues to strengthen its position through increasing investments in computational biology, precision medicine, and collaborative pharmaceutical research. Italy, Spain, and Russia are steadily expanding their drug discovery capabilities through digital transformation, biotechnology investments, and growing adoption of advanced discovery platforms. The Rest of Europe continues to benefit from expanding pharmaceutical innovation, supportive regulatory frameworks, and increasing cross-border research collaborations.

List of Key Companies Profiled

• Schrödinger, Inc.
• Certara, Inc.
• Dassault Systèmes SE
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Insilico Medicine
• Genedata AG
• Optibrium Ltd.
• HitGen Inc.
• Relay Therapeutics, Inc.

Europe Drug Discovery Platforms Market Report Segmentation

By Drug Type

• Small Molecule
• Large Molecule

By Application

• Lead Discovery
• Lead Optimization
• Target Identification
• Preclinical Testing
• Target Validation
• Other Applications

By End Use

• Biopharmaceutical Companies
• CROs/CDMOs
• Academic & Research Institutes

By Therapeutic Area

• Oncology
• Infectious & Immune System Diseases
• Neurology
• Cardiovascular Diseases
• Digestive System Diseases
• Other Therapeutic Areas

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Chapter 1. Europe Market
1.1 Market Overview
1.2 Key Factors Impacting Market
1.2.1 Market Drivers
1.2.2 Market Restraints
1.2.3 Market Opportunities
1.2.4 Market Challenges
1.2.5 Market Trends
1.2.6 State of Competition
1.2.7 Market Consolidation
1.2.8 Key Customer Criteria
1.3 Product Life Cycle
1.4 Segmentation By Drug Type
1.4.1 Small Molecule
1.4.2 Large Molecule
1.5 Segmentation By End Use
1.5.1 Biopharmaceutical Companies
1.5.2 CROs/CDMO
1.5.3 Academic and Research Institutes
1.6 Segmentation By Application
1.6.1 Lead Discovery
1.6.2 Lead Optimization
1.6.3 Target Identification
1.6.4 Preclinical Testing
1.6.5 Target Validation
1.6.6 Other Applications
1.7 Segmentation By Therapeutic
1.7.1 Oncology
1.7.2 Infectious and Immune System Diseases
1.7.3 Neurology
1.7.4 Cardiovascular Diseases
1.7.5 Digestive System Diseases
1.7.6 Other Therapeutic
1.8 Segmentation By Country
1.8.1 Germany
1.8.1.1 Segmentation By Drug Type
1.8.1.1.1 Small Molecule
1.8.1.1.2 Large Molecule
1.8.1.2 Segmentation By End Use
1.8.1.2.1 Biopharmaceutical Companies
1.8.1.2.2 CROs/CDMOs
1.8.1.2.3 Academic and Research Institutes
1.8.1.3 Segmentation By Application
1.8.1.3.1 Lead Discovery
1.8.1.3.2 Lead Optimization
1.8.1.3.3 Target Identification
1.8.1.3.4 Preclinical Testing
1.8.1.3.5 Target Validation
1.8.1.3.6 Other Application
1.8.1.4 Segmentation By Therapeutic
1.8.1.4.1 Oncology
1.8.1.4.2 Infectious and Immune System Diseases
1.8.1.4.3 Neurology
1.8.1.4.4 Cardiovascular Diseases
1.8.1.4.5 Digestive System Diseases
1.8.1.4.6 Other Therapeutic
1.8.2 UK
1.8.2.1 Segmentation By Drug Type
1.8.2.1.1 Small Molecule
1.8.2.1.2 Large Molecule
1.8.2.2 Segmentation By End Use
1.8.2.2.1 Biopharmaceutical Companies
1.8.2.2.2 CROs/CDMOs
1.8.2.2.3 Academic and Research Institutes
1.8.2.3 Segmentation By Application
1.8.2.3.1 Lead Discovery
1.8.2.3.2 Lead Optimization
1.8.2.3.3 Target Identification
1.8.2.3.4 Preclinical Testing
1.8.2.3.5 Target Validation
1.8.2.3.6 Other Application
1.8.2.4 Segmentation By Therapeutic
1.8.2.4.1 Oncology
1.8.2.4.2 Infectious and Immune System Diseases
1.8.2.4.3 Neurology
1.8.2.4.4 Cardiovascular Diseases
1.8.2.4.5 Digestive System Diseases
1.8.2.4.6 Other Therapeutic
1.8.3 France
1.8.3.1 Segmentation By Drug Type
1.8.3.1.1 Small Molecule
1.8.3.1.2 Large Molecule
1.8.3.2 Segmentation By End Use
1.8.3.2.1 Biopharmaceutical Companies
1.8.3.2.2 CROs/CDMOs
1.8.3.2.3 Academic and Research Institutes
1.8.3.3 Segmentation By Application
1.8.3.3.1 Lead Discovery
1.8.3.3.2 Lead Optimization
1.8.3.3.3 Target Identification
1.8.3.3.4 Preclinical Testing
1.8.3.3.5 Target Validation
1.8.3.3.6 Other Application
1.8.3.4 Segmentation By Therapeutic
1.8.3.4.1 Oncology
1.8.3.4.2 Infectious and Immune System Diseases
1.8.3.4.3 Neurology
1.8.3.4.4 Cardiovascular Diseases
1.8.3.4.5 Digestive System Diseases
1.8.3.4.6 Other Therapeutic
1.8.4 Russia
1.8.4.1 Segmentation By Drug Type
1.8.4.1.1 Small Molecule
1.8.4.1.2 Large Molecule
1.8.4.2 Segmentation By End Use
1.8.4.2.1 Biopharmaceutical Companies
1.8.4.2.2 CROs/CDMOs
1.8.4.2.3 Academic and Research Institutes
1.8.4.3 Segmentation By Application
1.8.4.3.1 Lead Discovery
1.8.4.3.2 Lead Optimization
1.8.4.3.3 Target Identification
1.8.4.3.4 Preclinical Testing
1.8.4.3.5 Target Validation
1.8.4.3.6 Other Application
1.8.4.4 Segmentation By Therapeutic
1.8.4.4.1 Oncology
1.8.4.4.2 Infectious and Immune System Diseases
1.8.4.4.3 Neurology
1.8.4.4.4 Cardiovascular Diseases
1.8.4.4.5 Digestive System Diseases
1.8.4.4.6 Other Therapeutic
1.8.5 Spain
1.8.5.1 Segmentation By Drug Type
1.8.5.1.1 Small Molecule
1.8.5.1.2 Large Molecule
1.8.5.2 Segmentation By End Use
1.8.5.2.1 Biopharmaceutical Companies
1.8.5.2.2 CROs/CDMOs
1.8.5.2.3 Academic and Research Institutes
1.8.5.3 Segmentation By Application
1.8.5.3.1 Lead Discovery
1.8.5.3.2 Lead Optimization
1.8.5.3.3 Target Identification
1.8.5.3.4 Preclinical Testing
1.8.5.3.5 Target Validation
1.8.5.3.6 Other Application
1.8.5.4 Segmentation By Therapeutic
1.8.5.4.1 Oncology
1.8.5.4.2 Infectious and Immune System Diseases
1.8.5.4.3 Neurology
1.8.5.4.4 Cardiovascular Diseases
1.8.5.4.5 Digestive System Diseases
1.8.5.4.6 Other Therapeutic
1.8.6 Italy
1.8.6.1 Segmentation By Drug Type
1.8.6.1.1 Small Molecule
1.8.6.1.2 Large Molecule
1.8.6.2 Segmentation By End Use
1.8.6.2.1 Biopharmaceutical Companies
1.8.6.2.2 CROs/CDMOs
1.8.6.2.3 Academic and Research Institutes
1.8.6.3 Segmentation By Application
1.8.6.3.1 Lead Discovery
1.8.6.3.2 Lead Optimization
1.8.6.3.3 Target Identification
1.8.6.3.4 Preclinical Testing
1.8.6.3.5 Target Validation
1.8.6.3.6 Other Application
1.8.6.4 Segmentation By Therapeutic
1.8.6.4.1 Oncology
1.8.6.4.2 Infectious and Immune System Diseases
1.8.6.4.3 Neurology
1.8.6.4.4 Cardiovascular Diseases
1.8.6.4.5 Digestive System Diseases
1.8.6.4.6 Other Therapeutic
1.8.7 Rest of Europe
1.8.7.1 Segmentation By Drug Type
1.8.7.1.1 Small Molecule
1.8.7.1.2 Large Molecule
1.8.7.2 Segmentation By End Use
1.8.7.2.1 Biopharmaceutical Companies
1.8.7.2.2 CROs/CDMOs
1.8.7.2.3 Academic and Research Institutes
1.8.7.3 Segmentation By Application
1.8.7.3.1 Lead Discovery
1.8.7.3.2 Lead Optimization
1.8.7.3.3 Target Identification
1.8.7.3.4 Preclinical Testing
1.8.7.3.5 Target Validation
1.8.7.3.6 Other Application
1.8.7.4 Segmentation By Therapeutic
1.8.7.4.1 Oncology
1.8.7.4.2 Infectious and Immune System Diseases
1.8.7.4.3 Neurology
1.8.7.4.4 Cardiovascular Diseases
1.8.7.4.5 Digestive System Diseases
1.8.7.4.6 Other Therapeutic


Chapter 2. Company Snapshot
2.1 Schrödinger, Inc.
2.1.1 Business Overview
2.1.2 Key Information
2.1.3 Company Focus
2.1.4 Strategic Insights
2.1.5 Strategy Deployed
2.1.6 Product & Service Portfolio
2.1.7 Capability Overview
2.1.8 Technology & Innovation Focus
2.1.9 Customers / End Users
2.1.10 Competitive Positioning
2.1.11 Key Differentiators
2.1.12 Portfolio Matrix
2.1.13 SWOT Analysis
2.1.14 Future Outlook
2.2 Certara, Inc.
2.2.1 Business Overview
2.2.2 Key Information
2.2.3 Company Focus
2.2.4 Strategic Insights
2.2.5 Strategy Deployed
2.2.6 Product & Service Portfolio
2.2.7 Capability Overview
2.2.8 Technology & Innovation Focus
2.2.9 Customers / End Users
2.2.10 Competitive Positioning
2.2.11 Key Differentiators
2.2.12 Portfolio Matrix
2.2.13 SWOT Analysis
2.2.14 Future Outlook
2.3 Optibrium Ltd.
2.3.1 Business Overview
2.3.2 Key Information
2.3.3 Company Focus
2.3.4 Strategic Insights
2.3.5 Strategy Deployed
2.3.6 Product & Service Portfolio
2.3.7 Capability Overview
2.3.8 Technology & Innovation Focus
2.3.9 Customers / End Users
2.3.10 Competitive Positioning
2.3.11 Key Differentiators
2.3.12 Portfolio Matrix
2.3.13 SWOT Analysis
2.3.14 Future Outlook
2.4 Dassault Systèmes SE
2.4.1 Business Overview
2.4.2 Key Information
2.4.3 Company Focus
2.4.4 Strategic Insights
2.4.5 Strategy Deployed
2.4.6 Product & Service Portfolio
2.4.7 Capability Overview
2.4.8 Technology & Innovation Focus
2.4.9 Customers / End Users 2.4.10 Competitive Positioning
2.4.11 Key Differentiators
2.4.12 Portfolio Matrix
2.4.13 SWOT Analysis
2.4.14 Future Outlook
2.5 Insilico Medicine
2.5.1 Business Overview
2.5.2 Key Information
2.5.3 Company Focus
2.5.4 Strategic Insights
2.5.5 Strategy Deployed
2.5.6 Product & Service Portfolio
2.5.7 Capability Overview
2.5.8 Technology & Innovation Focus
2.5.9 Customers / End Users
2.5.10 Competitive Positioning
2.5.11 Key Differentiators
2.5.12 Portfolio Matrix
2.5.13 SWOT Analysis
2.5.14 Future Outlook
2.6 Thermo Fisher Scientific, Inc.
2.6.1 Business Overview
2.6.2 Key Information
2.6.3 Company Focus
2.6.4 Strategic Insights
2.6.5 Strategy Deployed
2.6.6 Product & Service Portfolio
2.6.7 Capability Overview
2.6.8 Technology & Innovation Focus
2.6.9 Customers / End Users
2.6.10 Competitive Positioning
2.6.11 Key Differentiators
2.6.12 Portfolio Matrix
2.6.13 SWOT Analysis
2.6.14 Future Outlook
2.7 HitGen Inc.
2.7.1 Business Overview
2.7.2 Key Information
2.7.3 Company Focus
2.7.4 Strategic Insights
2.7.5 Strategy Deployed
2.7.6 Product & Service Portfolio
2.7.7 Capability Overview
2.7.8 Technology & Innovation Focus
2.7.9 Customers / End Users
2.7.10 Competitive Positioning
2.7.11 Key Differentiators
2.7.12 Portfolio Matrix
2.7.13 SWOT Analysis
2.7.14 Future Outlook
2.8 Genedata AG
2.8.1 Business Overview
2.8.2 Key Information
2.8.3 Company Focus
2.8.4 Strategic Insights
2.8.5 Strategy Deployed
2.8.6 Product & Service Portfolio
2.8.7 Capability Overview
2.8.8 Technology & Innovation Focus
2.8.9 Customers / End Users
2.8.10 Competitive Positioning
2.8.11 Key Differentiators
2.8.12 Portfolio Matrix
2.8.13 SWOT Analysis
2.8.14 Future Outlook
2.9 Relay Therapeutics, Inc.
2.9.1 Business Overview
2.9.2 Key Information
2.9.3 Company Focus
2.9.4 Strategic Insights
2.9.5 Strategy Deployed
2.9.6 Product & Service Portfolio
2.9.7 Capability Overview
2.9.8 Technology & Innovation Focus
2.9.9 Customers / End Users
2.9.10 Competitive Positioning
2.9.11 Key Differentiators
2.9.12 Portfolio Matrix
2.9.13 SWOT Analysis
2.9.14 Future Outlook
2.10 Merck KGaA
2.10.1 Business Overview
2.10.2 Key Information
2.10.3 Company Focus
2.10.4 Strategic Insights
2.10.5 Strategy Deployed
2.10.6 Product & Service Portfolio
2.10.7 Capability Overview
2.10.8 Technology & Innovation Focus
2.10.9 Customers / End Users
2.10.10 Competitive Positioning
2.10.11 Key Differentiators
2.10.12 Portfolio Matrix
2.10.13 SWOT Analysis
2.10.14 Future Outlook

List of Tables
Table 1 Europe Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
Table 2 Methodology for the research
Table 3 Key Factors Impacting Market
Table 4 Market Consolidation
Table 5 Key Customer Criteria
Table 6 Product Life Cycle
Table 7 Europe Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
Table 8 Europe Lead Discovery Market, 2022 - 2033, USD Million
Table 9 Europe Lead Optimization Market, 2022 - 2033, USD Million
Table 10 Europe Other Application Market, 2022 - 2033, USD Million
Table 11 Europe Preclinical Testing Market, 2022 - 2033, USD Million
Table 12 Europe Target Identification Market, 2022 - 2033, USD Million
Table 13 Europe Target Validation Market, 2022 - 2033, USD Million
Table 14 Europe Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
Table 15 Europe Large Molecule Market, 2022 - 2033, USD Million
Table 16 Europe Small Molecule Market, 2022 - 2033, USD Million
Table 17 Europe Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
Table 18 Europe Academic and Research Institutes Market, 2022 - 2033, USD Million
Table 19 Europe Biopharmaceutical Companies Market, 2022 - 2033, USD Million
Table 20 Europe CROs/CDMO Market, 2022 - 2033, USD Million
Table 21 Europe Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
Table 22 Europe Cardiovascular Diseases Market, 2022 - 2033, USD Million
Table 23 Europe Digestive System Diseases Market, 2022 - 2033, USD Million
Table 24 Europe Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
Table 25 Europe Neurology Market, 2022 - 2033, USD Million
Table 26 Europe Oncology Market, 2022 - 2033, USD Million
Table 27 Europe Other Therapeutic Market, 2022 - 2033, USD Million
Table 28 France Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
Table 29 Methodology for the research
Table 30 Key Factors Impacting Market
Table 31 Market Consolidation
Table 32 Key Customer Criteria
Table 33 Product Life Cycle
Table 34 France Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
Table 35 France Lead Discovery Market, 2022 - 2033, USD Million
Table 36 France Lead Optimization Market, 2022 - 2033, USD Million
Table 37 France Other Application Market, 2022 - 2033, USD Million
Table 38 France Preclinical Testing Market, 2022 - 2033, USD Million
Table 39 France Target Identification Market, 2022 - 2033, USD Million
Table 40 France Target Validation Market, 2022 - 2033, USD Million
Table 41 France Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
Table 42 France Large Molecule Market, 2022 - 2033, USD Million
Table 43 France Small Molecule Market, 2022 - 2033, USD Million
Table 44 France Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
Table 45 France Academic and Research Institutes Market, 2022 - 2033, USD Million
Table 46 France Biopharmaceutical Companies Market, 2022 - 2033, USD Million
Table 47 France CROs/CDMO Market, 2022 - 2033, USD Million
Table 48 France Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
Table 49 France Cardiovascular Diseases Market, 2022 - 2033, USD Million
Table 50 France Digestive System Diseases Market, 2022 - 2033, USD Million
Table 51 France Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
Table 52 France Neurology Market, 2022 - 2033, USD Million
Table 53 France Oncology Market, 2022 - 2033, USD Million
Table 54 France Other Therapeutic Market, 2022 - 2033, USD Million
Table 55 Germany Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
Table 56 Methodology for the research
Table 57 Key Factors Impacting Market
Table 58 Market Consolidation
Table 59 Key Customer Criteria
Table 60 Product Life Cycle
Table 61 Germany Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
Table 62 Germany Lead Discovery Market, 2022 - 2033, USD Million
Table 63 Germany Lead Optimization Market, 2022 - 2033, USD Million
Table 64 Germany Other Application Market, 2022 - 2033, USD Million
Table 65 Germany Preclinical Testing Market, 2022 - 2033, USD Million
Table 66 Germany Target Identification Market, 2022 - 2033, USD Million
Table 67 Germany Target Validation Market, 2022 - 2033, USD Million
Table 68 Germany Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
Table 69 Germany Large Molecule Market, 2022 - 2033, USD Million
Table 70 Germany Small Molecule Market, 2022 - 2033, USD Million
Table 71 Germany Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
Table 72 Germany Academic and Research Institutes Market, 2022 - 2033, USD Million
Table 73 Germany Biopharmaceutical Companies Market, 2022 - 2033, USD Million
Table 74 Germany CROs/CDMO Market, 2022 - 2033, USD Million
Table 75 Germany Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
Table 76 Germany Cardiovascular Diseases Market, 2022 - 2033, USD Million
Table 77 Germany Digestive System Diseases Market, 2022 - 2033, USD Million
Table 78 Germany Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
Table 79 Germany Neurology Market, 2022 - 2033, USD Million
Table 80 Germany Oncology Market, 2022 - 2033, USD Million
Table 81 Germany Other Therapeutic Market, 2022 - 2033, USD Million
Table 82 Italy Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
Table 83 Methodology for the research
Table 84 Key Factors Impacting Market
Table 85 Market Consolidation
Table 86 Key Customer Criteria
Table 87 Product Life Cycle
Table 88 Italy Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
Table 89 Italy Lead Discovery Market, 2022 - 2033, USD Million
Table 90 Italy Lead Optimization Market, 2022 - 2033, USD Million
Table 91 Italy Other Application Market, 2022 - 2033, USD Million
Table 92 Italy Preclinical Testing Market, 2022 - 2033, USD Million
Table 93 Italy Target Identification Market, 2022 - 2033, USD Million
Table 94 Italy Target Validation Market, 2022 - 2033, USD Million
Table 95 Italy Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
Table 96 Italy Large Molecule Market, 2022 - 2033, USD Million
Table 97 Italy Small Molecule Market, 2022 - 2033, USD Million
Table 98 Italy Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
Table 99 Italy Academic and Research Institutes Market, 2022 - 2033, USD Million
Table 100 Italy Biopharmaceutical Companies Market, 2022 - 2033, USD Million
Table 101 Italy CROs/CDMO Market, 2022 - 2033, USD Million
Table 102 Italy Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
Table 103 Italy Cardiovascular Diseases Market, 2022 - 2033, USD Million
Table 104 Italy Digestive System Diseases Market, 2022 - 2033, USD Million
Table 105 Italy Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
Table 106 Italy Neurology Market, 2022 - 2033, USD Million
Table 107 Italy Oncology Market, 2022 - 2033, USD Million
Table 108 Italy Other Therapeutic Market, 2022 - 2033, USD Million
Table 109 Russia Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
Table 110 Methodology for the research
Table 111 Key Factors Impacting Market
Table 112 Market Consolidation
Table 113 Key Customer Criteria
Table 114 Product Life Cycle
Table 115 Russia Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
Table 116 Russia Lead Discovery Market, 2022 - 2033, USD Million
Table 117 Russia Lead Optimization Market, 2022 - 2033, USD Million
Table 118 Russia Other Application Market, 2022 - 2033, USD Million
Table 119 Russia Preclinical Testing Market, 2022 - 2033, USD Million
Table 120 Russia Target Identification Market, 2022 - 2033, USD Million
Table 121 Russia Target Validation Market, 2022 - 2033, USD Million
Table 122 Russia Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
Table 123 Russia Large Molecule Market, 2022 - 2033, USD Million
Table 124 Russia Small Molecule Market, 2022 - 2033, USD Million
Table 125 Russia Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
Table 126 Russia Academic and Research Institutes Market, 2022 - 2033, USD Million
Table 127 Russia Biopharmaceutical Companies Market, 2022 - 2033, USD Million
Table 128 Russia CROs/CDMO Market, 2022 - 2033, USD Million
Table 129 Russia Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
Table 130 Russia Cardiovascular Diseases Market, 2022 - 2033, USD Million
Table 131 Russia Digestive System Diseases Market, 2022 - 2033, USD Million
Table 132 Russia Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
Table 133 Russia Neurology Market, 2022 - 2033, USD Million
Table 134 Russia Oncology Market, 2022 - 2033, USD Million
Table 135 Russia Other Therapeutic Market, 2022 - 2033, USD Million
Table 136 Spain Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
Table 137 Methodology for the research
Table 138 Key Factors Impacting Market
Table 139 Market Consolidation
Table 140 Key Customer Criteria
Table 141 Product Life Cycle
Table 142 Spain Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
Table 143 Spain Lead Discovery Market, 2022 - 2033, USD Million
Table 144 Spain Lead Optimization Market, 2022 - 2033, USD Million
Table 145 Spain Other Application Market, 2022 - 2033, USD Million
Table 146 Spain Preclinical Testing Market, 2022 - 2033, USD Million
Table 147 Spain Target Identification Market, 2022 - 2033, USD Million
Table 148 Spain Target Validation Market, 2022 - 2033, USD Million
Table 149 Spain Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
Table 150 Spain Large Molecule Market, 2022 - 2033, USD Million
Table 151 Spain Small Molecule Market, 2022 - 2033, USD Million
Table 152 Spain Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
Table 153 Spain Academic and Research Institutes Market, 2022 - 2033, USD Million
Table 154 Spain Biopharmaceutical Companies Market, 2022 - 2033, USD Million
Table 155 Spain CROs/CDMO Market, 2022 - 2033, USD Million
Table 156 Spain Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
Table 157 Spain Cardiovascular Diseases Market, 2022 - 2033, USD Million
Table 158 Spain Digestive System Diseases Market, 2022 - 2033, USD Million
Table 159 Spain Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
Table 160 Spain Neurology Market, 2022 - 2033, USD Million
Table 161 Spain Oncology Market, 2022 - 2033, USD Million
Table 162 Spain Other Therapeutic Market, 2022 - 2033, USD Million
Table 163 United Kingdom Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
Table 164 Methodology for the research
Table 165 Key Factors Impacting Market
Table 166 Market Consolidation
Table 167 Key Customer Criteria
Table 168 Product Life Cycle
Table 169 United Kingdom Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
Table 170 United Kingdom Lead Discovery Market, 2022 - 2033, USD Million
Table 171 United Kingdom Lead Optimization Market, 2022 - 2033, USD Million
Table 172 United Kingdom Other Application Market, 2022 - 2033, USD Million
Table 173 United Kingdom Preclinical Testing Market, 2022 - 2033, USD Million
Table 174 United Kingdom Target Identification Market, 2022 - 2033, USD Million
Table 175 United Kingdom Target Validation Market, 2022 - 2033, USD Million
Table 176 United Kingdom Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
Table 177 United Kingdom Large Molecule Market, 2022 - 2033, USD Million
Table 178 United Kingdom Small Molecule Market, 2022 - 2033, USD Million
Table 179 United Kingdom Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
Table 180 United Kingdom Academic and Research Institutes Market, 2022 - 2033, USD Million
Table 181 United Kingdom Biopharmaceutical Companies Market, 2022 - 2033, USD Million
Table 182 United Kingdom CROs/CDMO Market, 2022 - 2033, USD Million
Table 183 United Kingdom Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
Table 184 United Kingdom Cardiovascular Diseases Market, 2022 - 2033, USD Million
Table 185 United Kingdom Digestive System Diseases Market, 2022 - 2033, USD Million
Table 186 United Kingdom Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
Table 187 United Kingdom Neurology Market, 2022 - 2033, USD Million
Table 188 United Kingdom Oncology Market, 2022 - 2033, USD Million
Table 189 United Kingdom Other Therapeutic Market, 2022 - 2033, USD Million
Table 190 Rest of Europe Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
Table 191 Methodology for the research
Table 192 Key Factors Impacting Market
Table 193 Market Consolidation
Table 194 Key Customer Criteria
Table 195 Product Life Cycle
Table 196 Rest of Europe Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
Table 197 Rest of Europe Lead Discovery Market, 2022 - 2033, USD Million
Table 198 Rest of Europe Lead Optimization Market, 2022 - 2033, USD Million
Table 199 Rest of Europe Other Application Market, 2022 - 2033, USD Million
Table 200 Rest of Europe Preclinical Testing Market, 2022 - 2033, USD Million
Table 201 Rest of Europe Target Identification Market, 2022 - 2033, USD Million
Table 202 Rest of Europe Target Validation Market, 2022 - 2033, USD Million
Table 203 Rest of Europe Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
Table 204 Rest of Europe Large Molecule Market, 2022 - 2033, USD Million
Table 205 Rest of Europe Small Molecule Market, 2022 - 2033, USD Million
Table 206 Rest of Europe Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
Table 207 Rest of Europe Academic and Research Institutes Market, 2022 - 2033, USD Million
Table 208 Rest of Europe Biopharmaceutical Companies Market, 2022 - 2033, USD Million
Table 209 Rest of Europe CROs/CDMO Market, 2022 - 2033, USD Million
Table 210 Rest of Europe Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
Table 211 Rest of Europe Cardiovascular Diseases Market, 2022 - 2033, USD Million
Table 212 Rest of Europe Digestive System Diseases Market, 2022 - 2033, USD Million
Table 213 Rest of Europe Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
Table 214 Rest of Europe Neurology Market, 2022 - 2033, USD Million
Table 215 Rest of Europe Oncology Market, 2022 - 2033, USD Million
Table 216 Rest of Europe Other Therapeutic Market, 2022 - 2033, USD Million


List of Figures
FIG 1 Methodology for the research
FIG 2 Key Factors Impacting Market
FIG 3 Market Consolidation
FIG 4 Key Customer Criteria
FIG 5 Product Life Cycle
FIG 6 Europe Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
FIG 7 Europe Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
FIG 8 Europe Lead Discovery Market, 2022 - 2033, USD Million
FIG 9 Europe Lead Optimization Market, 2022 - 2033, USD Million
FIG 10 Europe Other Application Market, 2022 - 2033, USD Million
FIG 11 Europe Preclinical Testing Market, 2022 - 2033, USD Million
FIG 12 Europe Target Identification Market, 2022 - 2033, USD Million
FIG 13 Europe Target Validation Market, 2022 - 2033, USD Million
FIG 14 Europe Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
FIG 15 Europe Large Molecule Market, 2022 - 2033, USD Million
FIG 16 Europe Small Molecule Market, 2022 - 2033, USD Million
FIG 17 Europe Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
FIG 18 Europe Academic and Research Institutes Market, 2022 - 2033, USD Million
FIG 19 Europe Biopharmaceutical Companies Market, 2022 - 2033, USD Million
FIG 20 Europe CROs/CDMO Market, 2022 - 2033, USD Million
FIG 21 Europe Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
FIG 22 Europe Cardiovascular Diseases Market, 2022 - 2033, USD Million
FIG 23 Europe Digestive System Diseases Market, 2022 - 2033, USD Million
FIG 24 Europe Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
FIG 25 Europe Neurology Market, 2022 - 2033, USD Million
FIG 26 Europe Oncology Market, 2022 - 2033, USD Million FIG 27 Europe Other Therapeutic Market, 2022 - 2033, USD Million
FIG 28 France Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
FIG 29 France Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
FIG 30 France Lead Discovery Market, 2022 - 2033, USD Million
FIG 31 France Lead Optimization Market, 2022 - 2033, USD Million
FIG 32 France Other Application Market, 2022 - 2033, USD Million
FIG 33 France Preclinical Testing Market, 2022 - 2033, USD Million
FIG 34 France Target Identification Market, 2022 - 2033, USD Million
FIG 35 France Target Validation Market, 2022 - 2033, USD Million
FIG 36 France Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
FIG 37 France Large Molecule Market, 2022 - 2033, USD Million
FIG 38 France Small Molecule Market, 2022 - 2033, USD Million
FIG 39 France Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
FIG 40 France Academic and Research Institutes Market, 2022 - 2033, USD Million
FIG 41 France Biopharmaceutical Companies Market, 2022 - 2033, USD Million
FIG 42 France CROs/CDMO Market, 2022 - 2033, USD Million
FIG 43 France Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
FIG 44 France Cardiovascular Diseases Market, 2022 - 2033, USD Million
FIG 45 France Digestive System Diseases Market, 2022 - 2033, USD Million
FIG 46 France Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
FIG 47 France Neurology Market, 2022 - 2033, USD Million
FIG 48 France Oncology Market, 2022 - 2033, USD Million
FIG 49 France Other Therapeutic Market, 2022 - 2033, USD Million
FIG 50 Germany Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
FIG 51 Germany Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
FIG 52 Germany Lead Discovery Market, 2022 - 2033, USD Million
FIG 53 Germany Lead Optimization Market, 2022 - 2033, USD Million
FIG 54 Germany Other Application Market, 2022 - 2033, USD Million
FIG 55 Germany Preclinical Testing Market, 2022 - 2033, USD Million
FIG 56 Germany Target Identification Market, 2022 - 2033, USD Million
FIG 57 Germany Target Validation Market, 2022 - 2033, USD Million
FIG 58 Germany Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
FIG 59 Germany Large Molecule Market, 2022 - 2033, USD Million
FIG 60 Germany Small Molecule Market, 2022 - 2033, USD Million
FIG 61 Germany Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
FIG 62 Germany Academic and Research Institutes Market, 2022 - 2033, USD Million
FIG 63 Germany Biopharmaceutical Companies Market, 2022 - 2033, USD Million
FIG 64 Germany CROs/CDMO Market, 2022 - 2033, USD Million
FIG 65 Germany Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
FIG 66 Germany Cardiovascular Diseases Market, 2022 - 2033, USD Million
FIG 67 Germany Digestive System Diseases Market, 2022 - 2033, USD Million
FIG 68 Germany Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
FIG 69 Germany Neurology Market, 2022 - 2033, USD Million
FIG 70 Germany Oncology Market, 2022 - 2033, USD Million
FIG 71 Germany Other Therapeutic Market, 2022 - 2033, USD Million
FIG 72 Italy Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
FIG 73 Italy Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
FIG 74 Italy Lead Discovery Market, 2022 - 2033, USD Million
FIG 75 Italy Lead Optimization Market, 2022 - 2033, USD Million
FIG 76 Italy Other Application Market, 2022 - 2033, USD Million
FIG 77 Italy Preclinical Testing Market, 2022 - 2033, USD Million
FIG 78 Italy Target Identification Market, 2022 - 2033, USD Million
FIG 79 Italy Target Validation Market, 2022 - 2033, USD Million
FIG 80 Italy Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
FIG 81 Italy Large Molecule Market, 2022 - 2033, USD Million
FIG 82 Italy Small Molecule Market, 2022 - 2033, USD Million
FIG 83 Italy Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
FIG 84 Italy Academic and Research Institutes Market, 2022 - 2033, USD Million
FIG 85 Italy Biopharmaceutical Companies Market, 2022 - 2033, USD Million
FIG 86 Italy CROs/CDMO Market, 2022 - 2033, USD Million
FIG 87 Italy Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
FIG 88 Italy Cardiovascular Diseases Market, 2022 - 2033, USD Million
FIG 89 Italy Digestive System Diseases Market, 2022 - 2033, USD Million
FIG 90 Italy Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
FIG 91 Italy Neurology Market, 2022 - 2033, USD Million
FIG 92 Italy Oncology Market, 2022 - 2033, USD Million
FIG 93 Italy Other Therapeutic Market, 2022 - 2033, USD Million
FIG 94 Russia Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
FIG 95 Russia Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
FIG 96 Russia Lead Discovery Market, 2022 - 2033, USD Million
FIG 97 Russia Lead Optimization Market, 2022 - 2033, USD Million
FIG 98 Russia Other Application Market, 2022 - 2033, USD Million
FIG 99 Russia Preclinical Testing Market, 2022 - 2033, USD Million
FIG 100 Russia Target Identification Market, 2022 - 2033, USD Million
FIG 101 Russia Target Validation Market, 2022 - 2033, USD Million
FIG 102 Russia Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
FIG 103 Russia Large Molecule Market, 2022 - 2033, USD Million
FIG 104 Russia Small Molecule Market, 2022 - 2033, USD Million
FIG 105 Russia Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
FIG 106 Russia Academic and Research Institutes Market, 2022 - 2033, USD Million
FIG 107 Russia Biopharmaceutical Companies Market, 2022 - 2033, USD Million
FIG 108 Russia CROs/CDMO Market, 2022 - 2033, USD Million
FIG 109 Russia Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
FIG 110 Russia Cardiovascular Diseases Market, 2022 - 2033, USD Million
FIG 111 Russia Digestive System Diseases Market, 2022 - 2033, USD Million
FIG 112 Russia Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
FIG 113 Russia Neurology Market, 2022 - 2033, USD Million
FIG 114 Russia Oncology Market, 2022 - 2033, USD Million
FIG 115 Russia Other Therapeutic Market, 2022 - 2033, USD Million
FIG 116 Spain Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
FIG 117 Spain Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
FIG 118 Spain Lead Discovery Market, 2022 - 2033, USD Million
FIG 119 Spain Lead Optimization Market, 2022 - 2033, USD Million
FIG 120 Spain Other Application Market, 2022 - 2033, USD Million
FIG 121 Spain Preclinical Testing Market, 2022 - 2033, USD Million
FIG 122 Spain Target Identification Market, 2022 - 2033, USD Million
FIG 123 Spain Target Validation Market, 2022 - 2033, USD Million
FIG 124 Spain Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
FIG 125 Spain Large Molecule Market, 2022 - 2033, USD Million
FIG 126 Spain Small Molecule Market, 2022 - 2033, USD Million
FIG 127 Spain Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
FIG 128 Spain Academic and Research Institutes Market, 2022 - 2033, USD Million
FIG 129 Spain Biopharmaceutical Companies Market, 2022 - 2033, USD Million
FIG 130 Spain CROs/CDMO Market, 2022 - 2033, USD Million
FIG 131 Spain Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
FIG 132 Spain Cardiovascular Diseases Market, 2022 - 2033, USD Million
FIG 133 Spain Digestive System Diseases Market, 2022 - 2033, USD Million
FIG 134 Spain Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
FIG 135 Spain Neurology Market, 2022 - 2033, USD Million
FIG 136 Spain Oncology Market, 2022 - 2033, USD Million
FIG 137 Spain Other Therapeutic Market, 2022 - 2033, USD Million
FIG 138 United Kingdom Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
FIG 139 United Kingdom Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
FIG 140 United Kingdom Lead Discovery Market, 2022 - 2033, USD Million
FIG 141 United Kingdom Lead Optimization Market, 2022 - 2033, USD Million
FIG 142 United Kingdom Other Application Market, 2022 - 2033, USD Million
FIG 143 United Kingdom Preclinical Testing Market, 2022 - 2033, USD Million
FIG 144 United Kingdom Target Identification Market, 2022 - 2033, USD Million
FIG 145 United Kingdom Target Validation Market, 2022 - 2033, USD Million
FIG 146 United Kingdom Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
FIG 147 United Kingdom Large Molecule Market, 2022 - 2033, USD Million
FIG 148 United Kingdom Small Molecule Market, 2022 - 2033, USD Million
FIG 149 United Kingdom Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
FIG 150 United Kingdom Academic and Research Institutes Market, 2022 - 2033, USD Million
FIG 151 United Kingdom Biopharmaceutical Companies Market, 2022 - 2033, USD Million
FIG 152 United Kingdom CROs/CDMO Market, 2022 - 2033, USD Million
FIG 153 United Kingdom Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
FIG 154 United Kingdom Cardiovascular Diseases Market, 2022 - 2033, USD Million
FIG 155 United Kingdom Digestive System Diseases Market, 2022 - 2033, USD Million
FIG 156 United Kingdom Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
FIG 157 United Kingdom Neurology Market, 2022 - 2033, USD Million
FIG 158 United Kingdom Oncology Market, 2022 - 2033, USD Million
FIG 159 United Kingdom Other Therapeutic Market, 2022 - 2033, USD Million
FIG 160 Rest of Europe Drug Discovery Platforms Market Market, 2022 - 2033, USD Million
FIG 161 Rest of Europe Drug Discovery Platforms Market Market by Application, 2022 - 2033, USD Million
FIG 162 Rest of Europe Lead Discovery Market, 2022 - 2033, USD Million
FIG 163 Rest of Europe Lead Optimization Market, 2022 - 2033, USD Million
FIG 164 Rest of Europe Other Application Market, 2022 - 2033, USD Million
FIG 165 Rest of Europe Preclinical Testing Market, 2022 - 2033, USD Million
FIG 166 Rest of Europe Target Identification Market, 2022 - 2033, USD Million
FIG 167 Rest of Europe Target Validation Market, 2022 - 2033, USD Million
FIG 168 Rest of Europe Drug Discovery Platforms Market Market by Drug Type, 2022 - 2033, USD Million
FIG 169 Rest of Europe Large Molecule Market, 2022 - 2033, USD Million
FIG 170 Rest of Europe Small Molecule Market, 2022 - 2033, USD Million
FIG 171 Rest of Europe Drug Discovery Platforms Market Market by End Use, 2022 - 2033, USD Million
FIG 172 Rest of Europe Academic and Research Institutes Market, 2022 - 2033, USD Million
FIG 173 Rest of Europe Biopharmaceutical Companies Market, 2022 - 2033, USD Million
FIG 174 Rest of Europe CROs/CDMO Market, 2022 - 2033, USD Million
FIG 175 Rest of Europe Drug Discovery Platforms Market Market by Therapeutic, 2022 - 2033, USD Million
FIG 176 Rest of Europe Cardiovascular Diseases Market, 2022 - 2033, USD Million
FIG 177 Rest of Europe Digestive System Diseases Market, 2022 - 2033, USD Million
FIG 178 Rest of Europe Infectious and Immune System Diseases Market, 2022 - 2033, USD Million
FIG 179 Rest of Europe Neurology Market, 2022 - 2033, USD Million
FIG 180 Rest of Europe Oncology Market, 2022 - 2033, USD Million
FIG 181 Rest of Europe Other Therapeutic Market, 2022 - 2033, USD Million